Information Provided By: 
Fly News Breaks for March 5, 2018
AGN, EOLS
Mar 5, 2018 | 05:48 EDT
Cantor Fitzgerald analyst Louise Chen started Evolus (EOLS) with an Overweight rating and $25 price target. Physicians want a less costly alternative to Allergan's (AGN) Botox, Chen tells investors in a research note. She expects approval of DWP-450 before the end of the year and notes Evolus is planning to sell the neurotoxin at a 20%-25% discount to Botox.
News For EOLS;AGN From the Last 2 Days
There are no results for your query EOLS;AGN
